



To,

May 28, 2025

Asst. General Manager,
Dept. of Corporate Services
Bombay Stock Exchange Limited,
14th Floor, P.J. Towers, Dalal Street,
Fort, Mumbai: 400 001, Maharashtra, Mumbai.

Respected Sir,

Sub: Outcome of the Board Meeting held on Wednesday, May 28, 2025.

Reference: Adeshwar Meditex Ltd (ADESHWAR) Scrip Code: 543309

With reference to the above captioned subject, we wish to intimate your esteemed exchange that as decided in the Meeting of the Board of Directors of the Company held today, i.e. on May 28, 2025, for which intimation was already given to you, the Board of Directors has:

1. Taken on record the Audited Financial Results of the Company for the half and financial year ended March 31, 2025, along with the Audit Report;
2. Taken note of details of related party transactions for the year ended 31st March 2025.

Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), read with SEBI Circular CIR/CFD/CMD/56/2016 dated 27th May, 2016 on "Disclosure of the Impact of Audit Qualifications by the Listed Entities", we would like to confirm that Statutory Auditors of the Company, have issued Audit Reports with unmodified opinion on the above financial results.

In connection Point No.1, please find enclosed the copy of Audited Standalone financial Results of the Company for the half year and financial year ended March 31, 2025, along with the Audit Report by the Statutory Auditors of the Company as "**Annexure-I**".

In connection with Point No. 2, please find enclosed the copy of details of Related Party Transactions of the Company for the half year and financial year ended 31st March, 2025 as "**Annexure-II**"

The meeting commenced at 11.30 A.M (IST) and concluded at 11.45 A.M. (IST)

The above intimation is given to you for your record.

Thanking You,

Yours faithfully,

For Adeshwar Meditex Limited

(Formerly known as Adeshwar Meditex Limited Private Limited)

KRISHNOJIRAO
NAGARAJA RAO

Digitally signed by
KRISHNOJIRAO NAGARAJA
RAO
Date: 2025.05.28 12:04:17
+05'30'

Krishnojirao Nagaraja Rao

Director

DIN: 07684308

Encl: as above





DECLARATION

[Pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015]

Pursuant to the requirement as specified by Regulation 33 Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended by SEBI (Listing Obligation and Disclosure Requirements) (Amendment) Regulations, 2016 it is hereby declared by the Auditors Report for the financial year ended as on March 31, 2025 contains *unmodified opinion* as provided under the Independent Auditors' Report which is attached herewith for your reference.

You are kindly requested to take the above declaration in your records.

For Adeshwar Meditex Limited
(Formerly known as Adeshwar Meditex Limited Private Limited)

Digitally signed by
KRISHNOJIRAO
NAGARAJA RAO
Date: 2025.05.28
12:04:54 +05'30'

Krishnojirao Nagaraja Rao
Director
DIN: 07684308



Adeshwar Meditex Limited

CIN : L52390MH2007PLC169544

**Statement Of Audited Financial Results For The Half Year And Year Ended 31st March, 2025
(As Per Sch III of Companies Act. 2013 and Non-Ind AS)**

Particulars	(Rs. in Lakhs)				
	Half Year Ended 31.03.2025 (Audited)	Half Year Ended 30.09.2024 (Unaudited)	Half Year Ended 31.03.2024 (Audited)	Year Ended 31.03.2025 (Audited)	Year Ended 31.03.2024 (Audited)
Revenue From Operations	3,744.85	4,089.59	3,358.55	8,371.31	7,985.02
Other Income	17.41	21.02	4.84	25.86	13.28
Total Income	3,762.26	4,110.61	3,363.39	8,397.17	7,998.30
Expenses:					
Cost of Materials Consumed	3,722.93	3,561.58	3,682.82	7,358.22	7,318.10
Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	(367.15)	119.65	(788.30)	83.59	(337.56)
Employee Benefit Expense	144.46	78.19	101.32	219.61	176.48
Finance Costs	30.70	70.71	89.65	133.39	192.33
Depreciation and Amortisation Cost	21.21	24.70	31.40	49.94	60.13
Other Expenses	27.99	130.37	65.19	273.08	310.28
Total Expenses	3,580.15	3,985.20	3,182.08	8,117.83	7,719.76
Profit Before Prior Period Items ,Exceptional and Extraordinary Items and Tax	182.11	125.41	181.31	279.34	278.54
Tax Expense:					
(1) Current Tax	57.50	35.00	55.00	82.50	80.00
(2) Deferred Tax	9.29	-	1.83	9.73	2.27
Profit/(Loss) For The period	133.90	90.41	128.14	206.57	200.80
Earning Per Equity Share:					
Face Value Per Equity Shares Rs.10/- Fully Paid up.					
(1) Basic	0.93	0.63	0.89	1.43	1.39
(2) Diluted	0.93	0.63	0.89	1.43	1.39

As per our report of even date
For J N Gupta & Co. LLP
Chartered Accountants
ICAI F.R.No. 006569C/W100892

(Signature)
Digitally signed by CA Jagdish
Narain Gupta
Date: 2025.05.28 11:41:02 +05'30'

CA Jagdish N Gupta
Partner
M.No.: 400438
Date:- 28/05/2025
Place:- Mumbai

For & On Behalf of the Board
For Adeshwar Meditex Limited

(Signature)

Ashalata Baburao Raut
Managing Director
DIN : 02608730
Date:- 28/05/2025
Place:- Mumbai



Adeshwar Meditex Limited
CIN : LS2390MH2007PLC169544
Balance Sheet As At 31st March, 2025
(As Per Sch III of Companies Act, 2013 and Non-Ind AS)

(Rs. in Lakhs)

Particulars	31st March 2025	31st March 2024
I. EQUITY AND LIABILITIES		
(1) Shareholder's Funds		
(a) Share Capital	1,443.14	1,443.14
(b) Surplus	2,252.80	2,047.81
(2) Non-current liabilities		
(a) Long-Term Borrowings	194.05	105.89
(b) Long Term Provisions	42.94	33.54
(3) Current liabilities		
(a) Short-Term Borrowings	1,051.53	1,282.91
(b) Trade Payables		
(A) Total Outstanding Dues of Micro Enterprises and Small Enterprises; and	-	-
(B) Total Outstanding Dues of Creditors Other Than Micro Enterprises and Small Enterprises	2,121.40	1,452.59
(c) Other Current Liabilities	93.84	20.61
(d) Short-Term Provisions	20.35	17.13
Total	7,220.05	6,403.63
II. Assets		
(1) Non-Current Assets		
(a) Property, Plant and Equipment and Intangible Assets		
(i) Property, Plant and Equipment		
(b) Non-Current Investments	295.48	352.92
(c) Long Term Loans and Advances	-	9.80
(d) Deferred Tax Asset (Net)	92.12	103.28
(e) Other Non-Current Assets	23.27	13.54
	127.00	211.62
(2) Current Assets		
(a) Inventories	2,582.39	2,652.81
(b) Trade Receivables	3,498.29	2,527.16
(c) Cash and Bank Balances	280.62	115.77
(d) Short-Term Loans and Advances	301.79	398.92
(e) Other Current Assets	19.09	17.82
Total	7,220.05	6,403.63


As per our report of even date
For J N Gupta & Co LLP
Chartered Accountants
ICAI F.R.No. 006569C/W100892

 Digitally signed by CA.
Jagdish Narain Gupta
Date: 2025.05.28
11:40:40 +05'30'

CA Jagdish N Gupta
Partner
M.No.: 400438
Date:- 28-05-2025
Place:- Mumbai





For & On Behalf of the Board
For Adeshwar Meditex Limited



Ashalata Baburao Raut
Managing Director
DIN : 02608730
Date:- 28-05-2025
Place:- Mumbai



Adeshwar Meditex Limited		
CIN : L52390MH2007PLC169544		
Cash Flow Statement For The Year Ended March 31, 2025		
(Rs. in Lakhs)		
Particulars	For the Year ended March 31, 2025	For the Year ended March 31, 2024
A. CASH FLOW FROM OPERATING ACTIVITIES		
Net profit before tax and extraordinary items	279.34	278.54
Adjustments for:		
Depreciation and amortization expense	49.94	60.13
(Profit) / Loss on sale of fixed assets	0.64	-
Interest Paid	116.16	171.90
Interest Received	(10.72)	(15.21)
Gain on sale of Mutual Fund	(12.37)	-
Loang Term Provision For Gratuity	9.40	(4.49)
Share Issue Expenses	6.73	6.61
Operating profit / (loss) before working capital changes	439.12	497.48
Changes in working capital:		
Increase / (Decrease) in Inventories	70.42	(220.61)
Increase / (Decrease) in Payables	668.80	(225.96)
Increase / (Decrease) in Receivables	(971.13)	266.09
Increase / (Decrease) in deferred tax liabilities	-	-
Increase / (Decrease) in Short Term Provision	3.22	(1.93)
(Increase) / Decrease in Other current Liabilities	73.23	(6.30)
(Increase) / Decrease in Other Current Assets	(1.27)	(4.91)
(Increase) / Decrease in Other Non-Current Assets	84.62	31.60
Increase / (Decrease) in Short Term Loans and Advances	97.13	129.49
	25.02	(32.53)
CASH FLOW FROM / (USED IN) OPERATING ACTIVITIES	464.14	464.94
Less: Taxes paid	82.50	80.00
Less: Taxes for Earlier Years	1.59	1.01
NET CASH FLOW FROM / (USED IN) OPERATING ACTIVITIES	380.06	383.94
B. CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of tangible / intangible assets	(14.93)	(43.05)
Sale of tangible / intangible assets	22.42	-
(Increase) / Decrease in long term loan and advances	11.16	5.53
(Increase) / Decrease in non-current investments	9.80	-
(Profit)/Loss on redemption of investments (Mutual Fund)	12.37	-
Dividend/ bank interest received	10.72	15.21
Loss on sale of Fixed Assets	(0.64)	-
NET CASH FLOW FROM / (USED IN) INVESTING ACTIVITIES	50.91	(22.30)
C. CASH FLOW FROM FINANCING ACTIVITIES		
Interest expenses	(116.16)	(171.90)
Changes in Long Term Borrowing	88.16	(125.75)
Proceeds from Share Capital	-	-
Changes in Short Term Borrowing	(231.38)	(128.29)
Share Issue Expenses	(6.73)	(6.61)
Changes in Other Long Term Liabilities	-	(3.78)
Dividend paid	-	-
NET CASH FLOW FROM / (USED IN) FINANCING ACTIVITIES	(266.11)	(436.33)
NET INCREASE / (DECREASE) IN CASH & CASH EQUIVALENTS (A+B+C)	164.85	(74.69)
Cash and Cash equivalents at beginning period (Refer Note 18)	115.77	190.46
Cash and Cash equivalents at end of period (Refer Note 18)	280.62	115.77
D. Cash and Cash equivalents comprise of		
Cash on hand	1.95	9.13
Balances with banks		
In current accounts	278.67	106.64
Total	280.62	115.77
This Cash Flow Statement has been prepared as per "Indirect Method" as prescribed by Accounting Standard -3 (revised) "Cash Flow Statements"		
<p>As per our report of even date For J N Gupta & Co LLP Chartered Accountants ICAI F.R.No. 006569C/W100892</p> <p>Digitally signed by CA. Jagdish Narain Gupta Date: 2025.05.28 11:40:25 +05'30'</p> <p>CA Jagdish N Gupta Partner M.No.: 400438 Date:- 28-05-2025 Place:- Mumbai</p>	<p>For & On Behalf of the Board For Adeshwar Meditex Limited</p> <p><i>Ashalata</i></p> <p>Ashalata Baburao Raut Managing Director DIN : 02608730 Date:- 28-05-2025 Place:- Mumbai</p>	 

Notes:

1. The Audited Financial results were reviewed by the Audit Committee and taken on record by the Board of directors at their meeting held on 28th May, 2025.
2. As required under Regulation 33 of the SEBI (LODR) Regulations, 2015, the Statutory Auditors have issued Auditors Reports on the aforesaid Audited financial results for the half year ended & Year Ended on 31st March, 2025, which were also approved by the Audit Committee and Board at their meeting held on 28th May, 2025.
3. The Earning Per Sare (EPS) has been computed in accordance with the Accounting Standard on Earnings Per Share (AS 20).
4. The company is engaged in the Manufacturer and Trader of Sterile Wound Dressings, Combine Dressings, Gauze Dressing and Cotton Products, Medical Bandages and Plaster, Antiseptics / Disinfectants, First Aid Kits etc.
5. As per MCA Notification dated 16* February 2015, companies whose shares are listed on SME exchange as referred to in Chapter XB of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2009 are exempted from the compulsory requirement of adoption of IND-AS. As the company is covered under the exempted category, it has not adopted IND-AS for preparation of financial results.
6. Figures of Previous year/Period have been regrouped/recast wherever necessary, in order to make comparable.
7. No Investor complaints pending at the beginning of the period and no complaint were received during the period and pending for disposal at the end of period.

J N GUPTA & CO LLP

Chartered Accountants

501, Ruparel Iris, Senapati Bapat Marg, Matunga, Mumbai-400016

Contact No. 022-24323895, 9928762452, 9166145644

Email: jnguptacoho@gmail.com



Independent Auditor's Report on Standalone Half Yearly and Yearly Financial Results of the ADESHWAR MEDITEX LIMITED Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

Independent Auditor's Report

To
The Board of Directors of
ADESHWAR MEDITEX LIMITED

Opinion

We have audited the accompanying half yearly financial results ('the Statement') of **ADESHWAR MEDITEX LIMITED** ('the Company') for the half year ended on 31 March 2025, and the year to date results for the period from April 01, 2024 to March 31, 2025 prepared and being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (The 'Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid statements

- a) is presented in accordance with the requirements of Regulation 33 of the Regulations; and
- b) give the information required by the Companies Act, 2013 ("the Act") in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2025, and net profit and other financial information for the period ended on 31st March, 2025.

Basis for Opinion

We conducted our audit of the financial statements in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report.

We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical



requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the financial statements.

Management's Responsibility for Standalone Financial Results

This statement, is the responsibility of the Company's Management and approved by the Board of Directors has been compiled the basis of standalone financial statements for the year ended 31 March, 2025. The Company's Board of Directors are responsible for the preparation and presentation of the standalone Financial Results that gives true and fair view of the net profit and other comprehensive income and other financial information in accordance with the accounting principles generally accepted in India, including the accounting Standards specified under section 133 of the Act and in compliance with Regulation 33 of the listing Regulations.

This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, The Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the Standalone Financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists.

Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Standalone Financial results.



As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Standalone Financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. But not for the purpose of expressing an opinion on the effectiveness of such controls.
- Evaluate the appropriateness and reasonableness of disclosures made by Board of Directors in the term of the requirement specified under Regulation 33 of the Listing Regulation.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Standalone financial Results, including the disclosures and whether the Standalone financial Results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the Standalone Financial Results of the Company to Express an Opinion on the Standalone Financial Results.

Materiality is the magnitude of misstatements in the Standalone Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Standalone Financial Results may be influenced. We consider quantitative materiality and qualitative factors in –

1. Planning the scope of our audit work and in evaluating the results of our work; and
2. To evaluate the effect of any identified misstatements in the Standalone Financial Results.



We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matters

The Standalone Annual Financial Results dealt with by this report have been prepared for the express purpose of filing with Stock Exchanges. These results are based on and should be read with the audited Standalone Financial Statements of the Company for the year ended 31st March 2025 on which we issued an unmodified audit opinion.

The results include the results of the half year ended 31st March 2025, being the balancing figure between the audited figures in respect of the full financial year ended on 31st March 2025 and the published unaudited year-to-date figures up to the first half ended on 30th Sep, 2024 of the current financial year which were subjected to a limited review by us, as required under the Listing Regulations.

**As per our report of even date
For J N GUPTA & CO. LLP
Chartered Accountants
ICAI F.R.No. 006569C/W100892**

 Digitally signed by CA. Jagdish
Narain Gupta
Date: 2025.05.28 11:43:48 +05'30'

**CA Jagdish N Gupta
Partner
M.No.: 400438
Date: - 28-05-2025
Place: - Mumbai
UDIN: - 25400438BMHBVD5132**



ADESHWAR MEDITEX LIMITED

A+MEDITEX™



ISO 13485-2016 CERTIFIED COMPANY

(Previously Known As Adeshwar Meditex Pvt. Ltd.)

Manufacturer & Exporter of Medical Devices, Sterile / Non Sterile Wound Dressings, First Aid Kits & Pharmaceuticals Product Etc.

Regd. Office : Unit 111 Lok Centre, Marol Maroshi Road, Andheri (E), Marol Naka, Mumbai - 400 059, Maharashtra, India.

Tel. : 91-22-47835180

E-mail : adeshwarmedi@gmail.com, info@adeshwarmeditex.com

Web site : www.adeshwarmeditex.com, CIN : L52390MH2007PLC169544

Annexure II

Details of Related Party Transactions

Name of the related party	Relationship with the related party	Type of transaction	Amount of transaction (in Lakhs)
Mr. K Nagarajarao	Director - KMP	Salary	18.00
Mr. K Nagarajarao	Director - KMP	Loan Taken from Director	150.00
Mr. K Nagarajarao	Director - KMP	Interest Paid	8.46
Mr. Abhinandan N	Director - KMP	Salary	19.10
Mr. Abhinandan N	Director - KMP	Professional Fees	2.40
Mrs. Ashalata B. Raut	Director - KMP	Salary	30.00
Mrs. Ashalata B. Raut	Director - KMP	Loan taken from Director	10.00
Mrs. Ashalata B. Raut	Director - KMP	Interest Paid	0.34
Mr. Shailesh Rajpure	Director - KMP	Salary	12.00
M/s Moksha Biosurgicals Pvt Ltd	Associates / Enterprises with significant influence	Purchase & Labour Charges	3.31
M/s Moksha Biosurgicals Pvt Ltd	Associates / Enterprises with significant influence	Rent paid	10.80
M/s Shivadesh Meditex	Director is Proprietor	Purchase & Labour Charges	13.58
M/s Shivadesh Meditex	Director is Proprietor	Sales	45.56
Mr. Prashant Rane	Chief Financial Officer	Salary	6.00
Mr. Vishal Jain	Compliance Officer	Salary	3.60
Mr. Arun Shankar Koli	Independent Director	Director Seating Fees	0.28
Mr. Benegal Parameshwara Udpa	Independent Director	Director Seating Fees	0.28
Mr. Prithvi Sanjay Singh	Additional Non-Executive Director	Director Seating Fees	0.14

For Adeshwar Meditex Limited

(Formerly known as Adeshwar Meditex Limited Private Limited)

KRISHNOJIRA
O NAGARAJA
RAO

Digitally signed by
KRISHNOJIRA
NAGARAJA RAO
Date: 2025.05.28
12:03:04 +05'30'

Krishnojirao Nagaraja Rao

Director

DIN: 07684308



Factory : 17/18, Dewan & Sons Udyog Nagar, Palghar (West) 401 404. (M.S.) India.

Tel. : +91 - 2525 - 252058 / 250687 • Cell No. : +91 - 9325015511.

Customer Care No. : +91 - 9594062173